Nanjing Vishee Medical Technology Co (688580) Fair Value & Analysis
Healthcare · CN · Market cap 5.1B CNY
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Share price −13.7% over the past month.
A solid business, but screening 37% overvalued on our models.
What matters now
- A high-quality business (quality 71/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (¥39.23). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥20.34 – ¥166.81 · fair‑value band ¥23.54 – ¥39.23 · the ¥50.02 price screens above the ¥31.39 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Nanjing Vishee Medical Technology Co (688580) currently trades at ¥50.02, while our model-based Fair Value estimate is ¥31.39, implying the stock looks roughly 37.3% overvalued today. The Quality Score stands at 71/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Nanjing Vishee Medical Technology Co generated revenue of 473M CNY at a net margin of 35.2%. Revenue grew 10.6% year over year. It earns a return on equity of 9.7%. The balance sheet holds a net cash position of 1.1B CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥23.54 (bear case) to ¥39.23 (bull case); at ¥50.02, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -37%, 688580 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥34.49) versus Asset-Based (¥11.84). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Nanjing Vishee Medical Technology Co., Ltd provides rehabilitation meditation products and solutions in China and internationally.
Full company description
Nanjing Vishee Medical Technology Co., Ltd provides rehabilitation meditation products and solutions in China and internationally. The company offers MagNeuro, a transcranial magnetic stimulation (TMS) for use in anxiety disorders, movement disorders, and ADHD applications; MagNeuro ONE, a TMS therapy system with navigation for use in anxiety disorders applications; and MagBelle, a pelvic floor muscle stimulator for use in urinary incontinence, pelvic organ prolapse, chronic pelvic pain, vaginal laxity, and bowel dysfunction applications. It also provides MagGraver, a powered muscle stimulator for use in abdominal sculpting and body sculpting applications; RFIntima, a radiofrequency therapy product for use in pelvic floor dysfunction, genitourinary syndrome of menopause, and vulvar atrophy applications; and PicoV, a Nd:YAG picosecond laser system for use in pigmentary diseases, and tattoo removal and skin reconstruction applications. In addition, the company offers solutions to pelvic floor and postpartum rehabilitation, rehabilitation medicine, psychiatry, pediatric rehabilitation, and aesthetic medicine. Its products are used in various medical institutions, including hospitals, maternity specialty hospitals, psychiatric specialty hospitals, pediatric specialty hospitals, and rehabilitation specialty hospitals. The company was founded in 2001 and is headquartered in Nanjing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Nanjing Vishee Medical Technology Co reported revenue of ¥463M in FY2025 versus ¥430M in FY2021, a compound +1.8%/yr. Reported net income was ¥137M in FY2025, compounding −6.4%/yr from FY2021.
688580 screens 37% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Nanjing Vishee Medical Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Nanjing Vishee Medical Technology Co (688580) overvalued or undervalued?
What is the fair value of 688580?
What is the quality score of 688580?
What is the revenue of Nanjing Vishee Medical Technology Co (688580)?
What is the net profit margin of 688580?
Does Nanjing Vishee Medical Technology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Nanjing Vishee Medical Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.